UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Diabetes care, 2018-12, Vol.41 (12), p.2560-2569

2018

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

Cardiovascular diabetology, 2012-01, Vol.11 (1), p.3-3

2012

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis

Canadian journal of diabetes, 2016-02, Vol.40 (1), p.50-57

2016

Link zum Volltext

Verfügbarkeit prüfen

UCTM—An Ambidextrous Service Innovation Framework—A Bottom-Up Approach to Combine Human- and Technology-Centered Service Design

Systems (Basel), 2019-06, Vol.7 (2), p.23

2019

Link zum Volltext

Verfügbarkeit prüfen

Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial

Clinical infectious diseases, 2006-11, Vol.43 (10), p.1347-1356

2006

Link zum Volltext

Verfügbarkeit prüfen

Assessing augmented reality in production: remote-assisted maintenance with HoloLens

Procedia CIRP, 2020, Vol.88, p.139-144

2020

Link zum Volltext

Verfügbarkeit prüfen

Kidney Effects of Empagliflozin in People with Type 1 Diabetes

Clinical journal of the American Society of Nephrology, 2021-11, Vol.16 (11), p.1715-1719

2021

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

Cardiovascular diabetology, 2015-05, Vol.14 (1), p.57-57, Article 57

2015

Link zum Volltext

Verfügbarkeit prüfen

Log-based predictive maintenance in discrete parts manufacturing

Procedia CIRP, 2019, Vol.79, p.528-533

2019

Link zum Volltext

Verfügbarkeit prüfen

164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in youth with type 2 diabetes: a multicentre, randomised, double-blind, parallel group, phase 3 trial

The lancet. Diabetes & endocrinology, 2023-02, Vol.11 (3), p.169-181

2023

Link zum Volltext

Verfügbarkeit prüfen

Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials

Diabetes, obesity & metabolism, 2021-12, Vol.23 (12), p.2763-2774

2021

Link zum Volltext

Verfügbarkeit prüfen

Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1)

Diabetes technology & therapeutics, 2017-01, Vol.19 (1), p.49

2017

Link zum Volltext

Verfügbarkeit prüfen

994-P: DINAMO—Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents with Type 2 Diabetes (T2D) : Innovative Study Design and Baseline Characteristics

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Link zum Volltext

Verfügbarkeit prüfen

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

The Lancet (British edition), 2006-08, Vol.368 (9534), p.466-475

2006

Link zum Volltext

Verfügbarkeit prüfen

Medical applications of near-eye display devices: An exploratory study

International journal of surgery (London, England), 2014-12, Vol.12 (12), p.1266-1272

2014

Link zum Volltext

Verfügbarkeit prüfen

The activity-entity-impact method: understanding bottleneck behavior of simulation models demonstrated by an emergency department model

2019 Winter Simulation Conference (WSC), 2019, p.1148-1159

2019

Link zum Volltext
Volltext

Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy

Diabetes, obesity & metabolism, 2020-03, Vol.22 (3), p.427-433

2020

Link zum Volltext

Verfügbarkeit prüfen

1198-P: The M-EASE Studies: A Modeling and Simulation Approach to Further Characterize the Efficacy of Low-Dose Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes (T1DM)

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomized, double‐blind, placebo‐controlled dose‐finding study of the dipeptidyl peptidase‐4 inhibitor linagliptin in pediatric patients with type 2 diabetes

Pediatric diabetes, 2018-06, Vol.19 (4), p.640-648

2018

Link zum Volltext

Verfügbarkeit prüfen

Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment

Diabetes & vascular disease research, 2014-01, Vol.11 (1), p.34-40

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Cardiovascular (CV) Safety of Linagliptin as Add-on to Insulin in Type 2 Diabetes (T2D)—A Pooled Comprehensive Post-Hoc Analysis

Canadian journal of diabetes, 2014-10, Vol.38 (5), p.S57-S57

2014

Link zum Volltext

Verfügbarkeit prüfen

Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity : sub-analysis from RESIST

AIDS (London), 2007-09, Vol.21 (14), p.1977-1980

2007

Link zum Volltext

Verfügbarkeit prüfen

Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study

Journal of acquired immune deficiency syndromes (1999), 2007-08, Vol.45 (4), p.401

2007

Link zum Volltext

Verfügbarkeit prüfen

2.3 Cardiovascular (CV) Safety of Linagliptin in Patients with Type 2 Diabetes (T2D): A Pooled Comprehensive Analysis of Prospectively Adjudicated CV Events in Phase 3 Studies (376-OR)

Nederlands Tijdschrift voor Diabetolog, 2013-09, Vol.11 (3), p.83-84

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(26)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Life Sciences & Biomedicine
(17)
Humans
(14)
Endocrinology & Metabolism
(10)
Diabetes
(9)
Female
(8)
Male
(8)
Middle Aged
(7)
Aged
(6)
Diabetes Mellitus
(6)
Drug Therapy, Combination
(6)
Hiv Infections - Drug Therapy
(6)
Infectious Diseases
(6)
Insulin
(6)
Biological And Medical Sciences
(5)
Clinical Trials
(5)
Diabetes Mellitus, Type 2 - Drug Therapy
(5)
Human Viral Diseases
(5)
Immunology
(5)
Linagliptin
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis

UCTM—An Ambidextrous Service Innovation Framework—A Bottom-Up Approach to Combine Human- and Technology-Centered Service Design

Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial

Assessing augmented reality in production: remote-assisted maintenance with HoloLens

Kidney Effects of Empagliflozin in People with Type 1 Diabetes

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

Log-based predictive maintenance in discrete parts manufacturing

164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in youth with type 2 diabetes: a multicentre, randomised, double-blind, parallel group, phase 3 trial

Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials

Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1)

994-P: DINAMO—Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents with Type 2 Diabetes (T2D) : Innovative Study Design and Baseline Characteristics

Medical applications of near-eye display devices: An exploratory study

The activity-entity-impact method: understanding bottleneck behavior of simulation models demonstrated by an emergency department model

Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy

1198-P: The M-EASE Studies: A Modeling and Simulation Approach to Further Characterize the Efficacy of Low-Dose Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes (T1DM)

Randomized, double‐blind, placebo‐controlled dose‐finding study of the dipeptidyl peptidase‐4 inhibitor linagliptin in pediatric patients with type 2 diabetes

Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment

Efficacy and Cardiovascular (CV) Safety of Linagliptin as Add-on to Insulin in Type 2 Diabetes (T2D)—A Pooled Comprehensive Post-Hoc Analysis

Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity : sub-analysis from RESIST

Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study

2.3 Cardiovascular (CV) Safety of Linagliptin in Patients with Type 2 Diabetes (T2D): A Pooled Comprehensive Analysis of Prospectively Adjudicated CV Events in Phase 3 Studies (376-OR)

Suchergebnisse filtern